Purpose Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have
rarely been analyzed. The purpose of the present study was to find clinical and pathological …

Objective To report the experience of a single center for the selection of radioiodine-
refractory (RAIR) thyroid cancer patients (RAIR-TC) who needed tyrosine kinase inhibitor …

2693 Introduction: RAIR-DTC is an uncommon entity, occurring with an estimated incidence
of 4-5 cases/year/million people. A 10-year survival rate of RAIR-DTC is usually less than …

Background: Recently, radioiodine refractory differentiated thyroid cancer (RR-DTC) has
received increasing attention due to its poor prognosis. The roles of clinical, pathological …

Objective The purpose of the present study was to evaluate the clinical features of patients
with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an …

Aim Differentiated thyroid carcinoma (DTC) is the most prevalent endocrine malignancy, with
radioactive iodine (RAI) therapy being a standard of care. However, RAI refractoriness …

Background Radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has
received increasing attention due to its poor prognosis. However, outcomes may vary …

Background Patients with differentiated thyroid cancer (DTC) usually have an excellent
prognosis; however, 5%–15% develop radioactive iodine-refractory (RAIR) DTC (RAIR …

Background Differentiated thyroid carcinoma (DTC) originates from abnormal follicular cells
and accounts for approximately 90–95% of thyroid malignancies. The diagnosis of …

Background: Six to 20% of thyroid cancer (TC) patients develop distant metastases, and one-
third become radioiodine refractory (RAIR). Available targeted therapies increase …